ArticleJournal of clinical movement disorders2020
Potential impact and challenges associated with Parkinson's disease patient care amidst the COVID-19 global pandemic.
Article in Journal of clinical movement disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- The impact of Covid-19 restrictions in Ireland on symptom severity in mild to moderate Parkinson's disease.The British journal of occupational therapy · 2023Article
- Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease.Journal of neurology · 2022Article
- Low online search interest in teleneurology before and during COVID-19 pandemic: an infodemiological study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Effects of the COVID-19 Pandemic on Parkinson's Disease: a Single-Centered Qualitative Study.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2022Article
- Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease.Oxidative medicine and cellular longevity · 2022Review
- Spotlight on non-motor symptoms and Covid-19.International review of neurobiology · 2022Article
- MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice.Diagnostics (Basel, Switzerland) · 2021Article
- Therapeutic approaches for SARS-CoV-2 infection.Methods (San Diego, Calif.) · 2021Review
- Mental health in people with Parkinson's disease during the COVID-19 pandemic: potential for targeted interventions?NPJ Parkinson's disease · 2021Article
- Management of Parkinson's Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination.Journal of movement disorders · 2021Article
- Parkinson's Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy.Journal of movement disorders · 2021Article
- COVID-19 social distancing: negative effects on people with Parkinson disease and their associations with confidence for self-management.BMC neurology · 2021Article
- Alzheimer's and Parkinson's Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study.Geriatrics (Basel, Switzerland) · 2021Article
- Care of Parkinson's disease (PD) patients in times of covid-19 pandemic.Diabetes & metabolic syndromeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 has made itself known to health care providers and families across the world in a matter of months. While primarily a respiratory disorder, it has also been shown to cause neurological symptoms, which can be a concern for Parkinson's disease (PD) patients. Although PD is not as common as other conditions such as cardiovascular diseases, it affects millions of patients around the world whose care has been affected by the global pandemic.
objectivesThe aim of this review is to provide insight into the direct and indirect associations between COVID-19 and PD patient care.
resultsPotential direct effects of COVID-19 include possible neurodegeneration, concerns of symptom self-management with over-the-counter (OTC) products and ICU challenges that can arise in PD patients. In addition, a subset of PD patients may be at higher risk of severe COVID-19 infection. The indirect effects of the pandemic are associated with the social distancing measures and disruptions in health care systems and PD clinical trials, which may negatively affect PD patients' mental wellbeing and create barriers in controlling their PD symptoms. On a more positive note, telemedical care is quickly emerging as a primary communication tool for virtual patient care. However, further research should be conducted to examine the applicability of telemedicine across the entire PD population, such as those with more severe symptoms living in less developed areas. With all the uncertainty during this time, it is hopeful to hear many promising COVID-19 treatments being researched, one of them being a PD drug therapy, amantadine.
conclusionHopefully, we can consider this pandemic an opportunity to strengthen the PD community and learn more about the impact of the SARS-COV-2 virus. This review provides an overview of the interaction between COVID-19 and PD patients and future investigational retrospective studies are suggested to validate the observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.